Paolone G
Front Neurol. 2020; 11:557928.
PMID: 33117258
PMC: 7575743.
DOI: 10.3389/fneur.2020.557928.
Shen C, Xian W, Zhou H, Chen L, Pei Z
Exp Ther Med. 2016; 12(5):2803-2810.
PMID: 27882077
PMC: 5103691.
DOI: 10.3892/etm.2016.3736.
Das S, Patel B, Patri M
J Toxicol. 2016; 2016:8606410.
PMID: 27034665
PMC: 4789478.
DOI: 10.1155/2016/8606410.
Mpofana T, Daniels W, Mabandla M
Parkinsons Dis. 2016; 2016:6438783.
PMID: 26881180
PMC: 4735931.
DOI: 10.1155/2016/6438783.
Bai X, Hussong S
J Biochem Pharmacol Res. 2015; 2(2):54-56.
PMID: 26405617
PMC: 4578241.
Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells.
Zhou J, Tian G, Wang J, Luo X, Zhang S, Li J
Neural Regen Res. 2014; 7(34):2689-97.
PMID: 25337115
PMC: 4200737.
DOI: 10.3969/j.issn.1673-5374.2012.34.006.
Modeling fall propensity in Parkinson's disease: deficits in the attentional control of complex movements in rats with cortical-cholinergic and striatal-dopaminergic deafferentation.
Kucinski A, Paolone G, Bradshaw M, Albin R, Sarter M
J Neurosci. 2013; 33(42):16522-39.
PMID: 24133257
PMC: 6618519.
DOI: 10.1523/JNEUROSCI.2545-13.2013.
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.
Bezard E, Yue Z, Kirik D, Spillantini M
Mov Disord. 2012; 28(1):61-70.
PMID: 22753348
PMC: 3517687.
DOI: 10.1002/mds.25108.
Gβ5-RGS complexes are gatekeepers of hyperactivity involved in control of multiple neurotransmitter systems.
Xie K, Ge S, Collins V, Haynes C, Renner K, Meisel R
Psychopharmacology (Berl). 2011; 219(3):823-34.
PMID: 21766168
PMC: 3260372.
DOI: 10.1007/s00213-011-2409-y.
Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.
Yokoyama H, Uchida H, Kuroiwa H, Kasahara J, Araki T
Neurol Sci. 2010; 32(1):1-7.
PMID: 21107876
DOI: 10.1007/s10072-010-0424-0.
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H
Metab Brain Dis. 2010; 25(3):305-13.
PMID: 20957419
DOI: 10.1007/s11011-010-9212-z.
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H
Metab Brain Dis. 2010; 25(2):135-43.
PMID: 20424905
DOI: 10.1007/s11011-010-9191-0.
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T
J Mol Neurosci. 2009; 39(1-2):211-9.
PMID: 19199078
DOI: 10.1007/s12031-009-9181-z.
Dopamine and reward: the anhedonia hypothesis 30 years on.
Wise R
Neurotox Res. 2008; 14(2-3):169-83.
PMID: 19073424
PMC: 3155128.
DOI: 10.1007/BF03033808.
Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.
Kostrzewa R, Kostrzewa J, Brown R, Nowak P, Brus R
Neurotox Res. 2008; 14(2-3):121-8.
PMID: 19073420
DOI: 10.1007/BF03033804.
Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice.
Palmiter R
Ann N Y Acad Sci. 2008; 1129:35-46.
PMID: 18591467
PMC: 2720267.
DOI: 10.1196/annals.1417.003.
Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway.
Yuan Y, Jin J, Yang B, Zhang W, Hu J, Zhang Y
Cell Mol Neurobiol. 2007; 28(1):21-33.
PMID: 17712623
PMC: 11515038.
DOI: 10.1007/s10571-007-9185-6.
LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.
ONeill M, Murray T, Clay M, Lindstrom T, Yang C, Nisenbaum E
CNS Drug Rev. 2005; 11(1):77-96.
PMID: 15867954
PMC: 6741716.
DOI: 10.1111/j.1527-3458.2005.tb00037.x.
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Tillerson J, Cohen A, Caudle W, Zigmond M, Schallert T, Miller G
J Neurosci. 2002; 22(15):6790-9.
PMID: 12151559
PMC: 6758159.
DOI: 20026651.
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D
J Neurosci. 2001; 21(17):6853-61.
PMID: 11517273
PMC: 6763089.
